{"id":"NCT02163759","sponsor":"Hoffmann-La Roche","briefTitle":"A Study Comparing the Efficacy and Safety of Etrolizumab With Adalimumab and Placebo in Participants With Moderate to Severe Ulcerative Colitis (UC) in Participants Naive to Tumor Necrosis Factor (TNF) Inhibitors","officialTitle":"Phase III, Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy (Induction of Remission) and Safety of Etrolizumab Compared With Adalimumab and Placebo in Patients With Moderate to Severe Ulcerative Colitis Who Are Naive to TNF Inhibitors","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2014-11-04","primaryCompletion":"2020-02-19","completion":"2020-03-19","firstPosted":"2014-06-16","resultsPosted":"2021-04-05","lastUpdate":"2021-07-23"},"enrollment":358,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Ulcerative Colitis"],"interventions":[{"type":"DRUG","name":"Adalimumab","otherNames":["Humira"]},{"type":"OTHER","name":"Adalimumab Placebo","otherNames":[]},{"type":"DRUG","name":"Etrolizumab","otherNames":["PRO145223","RO5490261","RG7413"]},{"type":"OTHER","name":"Etrolizumab Placebo","otherNames":[]}],"arms":[{"label":"Placebo","type":"PLACEBO_COMPARATOR"},{"label":"Adalimumab","type":"ACTIVE_COMPARATOR"},{"label":"Etrolizumab","type":"EXPERIMENTAL"}],"summary":"This Phase III, double-blind, placebo and active-comparator controlled, multicenter study will investigate the efficacy and safety of etrolizumab in induction of remission in participants with moderately to severely active ulcerative colitis (UC) who are na√ève to tumor necrosis factor (TNF) inhibitors and refractory to or intolerant of prior immunosuppressant and/or corticosteroid treatment. In addition to this study, a second Phase III trial with identical study design (GA28949; NCT02171429) was independently conducted.","primaryOutcome":{"measure":"Percentage of Participants in Remission at Week 10 With Etrolizumab as Compared With Placebo, as Determined by the Mayo Clinic Score (MCS), GA28948 Population","timeFrame":"Week 10","effectByArm":[{"arm":"Placebo","deltaMin":6.9,"sd":null},{"arm":"Etrolizumab","deltaMin":19.4,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.0173"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":10,"exclusionCount":null},"locations":{"siteCount":88,"countries":["United States","Argentina","Australia","Brazil","Bulgaria","Estonia","France","Hong Kong","Mexico","Poland","Russia","Serbia","Slovakia","Ukraine"]},"refs":{"pmids":["34798036","32445184"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":2,"n":72},"commonTop":["Colitis ulcerative","Headache"]}}